JBIO · Jade Biosciences, Inc. · Executive Compensation
$14.07
-0.05 (-0.35%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$917.07M
Shares
63.60M
Volume · Oct 5
607.06K
Avg daily vol (3M)
898.64K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Tom Frohlich | Chief Executive Officer, President and Director | $9,799,759 |
| Andrew King | President, Research and Development | $4,541,804 |
| Bradford Dahms | Chief Financial Officer | $4,131,991 |
| Timothy P. Noyes | Former Chief Executive Officer | $1,814,483 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Timothy P. Noyes | Former Chief Executive Officer | $3,391,536 |
| Tom Frohlich | Chief Executive Officer, President and Director | $1,364,396 |
| Andrew King | President, Research and Development | $751,605 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Timothy P. Noyes | Chief Executive Officer | $5,305,461 |
| Benjamin T. Dake | President, Chief Operating Officer and Secretary | $2,878,821 |
| George A. Eldridge | Chief Financial Officer | $1,690,904 |
| Hunter Gillies | M.B.Ch.B. Chief Medical Officer | $1,632,478 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Benjamin T. Dake | President, Chief Operating Officer and Secretary | $502,119 |
| Hunter Gillies | M.B.Ch.B. Chief Medical Officer | $423,441 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mark Eisner, M.D., M.P.H. | Class I director | Appointed | 2026-06-26 |
| Andrew King | President, Research & Development | Appointed | 2026-04-22 |
| Hetal Kocinsky, M.D. | Chief Medical Officer | Resigned | 2025-09-09 |
| Bradford Dahms | Chief Financial Officer and Treasurer | Appointed | 2025-07-01 |
| Eric Dobmeier | Chair of the Board | Appointed | 2025-05-01 |
| Eric Dobmeier | Chair of the Board | Appointed | 2025-05-01 |
| Erin Lavelle | Board of Directors | Appointed | 2025-05-01 |
| Lawrence Klein | Board of Directors | Appointed | 2025-05-01 |
| Tomas Kiselak | Board of Directors | Appointed | 2025-05-01 |
| Tom Frohlich | Board of Directors | Appointed | 2025-05-01 |
| Christopher Cain | Board of Directors | Appointed | 2025-05-01 |
| Eric Dobmeier | Board of Directors | Appointed | 2025-05-01 |
| Elizabeth Balta | General Counsel and Corporate Secretary | Appointed | 2025-05-01 |
| Hetal Kocinsky | the Company's Chief Medical Officer | Appointed | 2025-05-01 |
| Jonathan Quick | the Company's Senior Vice President, Finance and Treasurer | Appointed | 2025-05-01 |
| Andrew King | the Company's Chief Scientific Officer & Head of Research and Development | Appointed | 2025-05-01 |
| George A. Eldridge | Aerovate's Chief Financial Officer | Terminated | 2025-05-01 |
| Tom Frohlich | the Company's Chief Executive Officer | Appointed | 2025-05-01 |
| Timothy P. Noyes | Aerovate's Chief Executive Officer | Terminated | 2025-05-01 |
| Donald Santel | Aerovate's board of directors | Resigned | 2025-05-01 |
| Mark Iwicki | Aerovate's board of directors | Resigned | 2025-05-01 |
| Joshua Resnick | Aerovate's board of directors | Resigned | 2025-05-01 |
| David Grayzel | Aerovate's board of directors | Resigned | 2025-05-01 |
| Allison Dorval | Aerovate's board of directors | Resigned | 2025-05-01 |
| Habib Dable | Aerovate's board of directors | Resigned | 2025-05-01 |